Business
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)
SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts. On behalf
About this update from Biocardia, Inc.
[{"type":"image","alt":"BioCardia, Inc.","displaySize":"","headline":null,"caption":"BioCardia, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qoNytrtYWwAQFfByGKCPTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300","width":300,"height":68}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced echocardiography data for the CardiAMP Cell Therapy for the treatment of heart failure has been accepted for Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting, which takes place March 2-4 in Boston, Massachusetts.","length":489,"tagName":"p"},{"type":"text","content":"On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal Investigator.","length":222,"tagName":"p"},{"type":"text","content":"Presentation Title: “Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial.”","length":238,"tagName":"p"},{"type":"text","content":"Presentation Session: THT Late Breaking Clinical Trial Oral Presentation on March 2 at 2pm EST.","length":95,"tagName":"p"},{"type":"text","content":"About CardiAMP Autologous Cell Therapy","length":38,"tagName":"p"},{"type":"text","content":"Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase capillary density and reduce tissue fibrosis of myocardial tissue to address microvascular dysfunction. Clinical development of the CardiAMP Cell Therapy for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Centers for Medicare and Medicaid Services (CM...